Full-Time

Senior Medical Director

Respiratory

Confirmed live in the last 24 hours

Kymera Therapeutics

Kymera Therapeutics

201-500 employees

Develops targeted protein degradation therapies

Biotechnology
Healthcare

Senior

Belmont, MA, USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • Advanced degree in medicine (e.g., M.D. or D.O. or equivalent). Clinical training in Pulmonary & Critical Care Medicine (board certified or eligible) is preferred.
  • Minimum of 6 years of industry experience, with a focus on late clinical development; strong academic backgrounds with less experience may also be considered.
  • Experience in inflammatory and immunological therapeutic areas is required; respiratory experience is advantageous.
  • Proven expertise in leading late-stage clinical trials, including protocol design, study start-up, team management, data analysis, and medical monitoring.
  • Experience with Investigational New Drug (IND) applications; experience with New Drug Applications (NDA) is a plus.
  • Demonstrated capability as a clinical development representative on cross-functional drug development teams.
  • In-depth knowledge of regulatory filings and interactions with health authorities.
  • Thorough understanding of all phases of drug development.
  • Exceptional communication skills with the ability to effectively present and engage a wide range of stakeholders.
Responsibilities
  • Design and implement comprehensive global clinical development plans as the Clinical Lead on cross-functional teams, ensuring integration of scientific rigor and innovation.
  • Develop and execute innovative strategies to expedite development cycles, focusing on efficient design and execution of Phase 2 and Phase 3 programs.
  • Act as a clinical leader, engaging with academic advisors, principal investigators, patient groups, regulatory authorities, and industry collaborators.
  • Utilize specialized knowledge in immunology and respiratory fields to support and enhance the clinical portfolio.
  • Collaborate with regulatory leaders to develop and execute submission strategies, overseeing the creation and quality of clinical content for protocols, INDs, and regulatory reports, and ensuring the highest standards for all clinical documents and regulatory responses.
  • Provide strategic input on next-generation targets in collaboration with discovery teams and lead the planning of Phase 1 clinical testing.
  • Serve as Medical Monitor and sponsor representative with CROs, PIs, core laboratories and other organizations involved in clinical trials.
  • Ensure timely execution of assets and studies within the immunology and respiratory portfolio.
  • Develop and implement publication strategies, and actively contribute to key presentations.

Kymera Therapeutics develops treatments by targeting and breaking down specific proteins that contribute to diseases, particularly cancer and immune disorders. Their main technology, the Pegasus Platform, enables them to identify these harmful proteins and create drug candidates aimed at effectively treating various conditions. Unlike many competitors, Kymera focuses on targeted protein degradation, which can lead to more precise therapies. The company's goal is to create next-generation medicines that address unmet medical needs, supported by partnerships with organizations like Sanofi to enhance their research and development efforts.

Company Stage

IPO

Total Funding

$191.6M

Headquarters

Cambridge, Massachusetts

Founded

2016

Growth & Insights
Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Kymera raised $225M and $275M in public offerings to fund R&D.
  • Partnership with Neosphere advances molecular glue target discovery.
  • HSBC's investment shows confidence in Kymera's protein degradation technology.

What critics are saying

  • Competition from Arvinas and Nurix may impact Kymera's market share.
  • Potential clinical trial delays could affect drug development timelines.
  • Reliance on partnerships like Sanofi poses revenue and R&D risks.

What makes Kymera Therapeutics unique

  • Kymera's Pegasus Platform enables precise targeting of disease-causing proteins.
  • The company focuses on developing orally administered therapies like KT-294.
  • Kymera's strategic partnership with Sanofi enhances its drug development capabilities.

Help us improve and share your feedback! Did you find this helpful?